Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sonnet BioTherapeutics Holdings's EV-to-OCF or its related term are showing as below:
SONN'
s EV-to-OCF Range Over the Past 10 Years
Min: -19.07 Med: -0.25 Max: 0.31
Current: -0.81
During the past 6 years, the highest EV-to-OCF of Sonnet BioTherapeutics Holdings was 0.31. The lowest was -19.07. And the median was -0.25.
SONN's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.72
vs SONN: -0.81
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sonnet BioTherapeutics Holdings's PE Ratio (TTM) for today is calculated as:
Sonnet BioTherapeutics Holdings's share price for today is $1.26.
Sonnet BioTherapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sonnet BioTherapeutics Holdings EV-to-OCF Related Terms
Sonnet BioTherapeutics Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonnet BioTherapeutics Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sonnet BioTherapeutics Holdings's EV-to-OCF falls into.
Sonnet BioTherapeutics Holdings's current Enterprise Value is $8.35 Mil.
Sonnet BioTherapeutics Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonnet BioTherapeutics Holdings (SONN) has a EV-to-OCF of -0.81 as of Aug. 30, 2026.
Is Sonnet BioTherapeutics Holdings' EV-to-OCF too high?
Sonnet BioTherapeutics Holdings' current EV-to-OCF is -0.81. Overall, Sonnet BioTherapeutics Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sonnet BioTherapeutics Holdings' EV-to-OCF compare to CING and BOLD?
Sonnet BioTherapeutics Holdings' EV-to-OCF of -0.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Sonnet BioTherapeutics Holdings's current EV-to-OCF is -0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonnet BioTherapeutics Holdings stock overvalued right now?
Sonnet BioTherapeutics Holdings (SONN) has a current EV-to-OCF of -0.81. The current EV-to-OCF is -0.81. Sonnet BioTherapeutics Holdings' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sonnet BioTherapeutics Holdings (SONN), the current EV-to-OCF is -0.81 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
28GF Score
Get the complete analysis for SONN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SONN has been successfully added to your 
